Literature DB >> 33595388

Intratumoral Hypoxia and Mechanisms of Immune Evasion Mediated by Hypoxia-Inducible Factors.

Gregg L Semenza1.   

Abstract

Activation of the innate and adaptive immune systems represents a promising strategy for defeating cancer. However, during tumor progression, cancer cells battle to shift the balance from immune activation to immunosuppression. Critical sites of this battle are regions of intratumoral hypoxia, and a major driving force for immunosuppression is the activity of hypoxia-inducible factors, which regulate the transcription of large batteries of genes in both cancer and stromal cells that block the infiltration and activity of cytotoxic T lymphocytes and natural killer cells, while stimulating the infiltration and activity of regulatory T cells, myeloid-derived suppressor cells, and tumor-associated macrophages. Targeting hypoxia-inducible factors or their target gene products may restore anticancer immunity and improve the response to immunotherapies.

Entities:  

Keywords:  CTLA4; HIF-1α; HIF-2α; PD1; PDL1; oxygen

Year:  2021        PMID: 33595388     DOI: 10.1152/physiol.00034.2020

Source DB:  PubMed          Journal:  Physiology (Bethesda)        ISSN: 1548-9221


  9 in total

1.  Hypoxia signaling: Challenges and opportunities for cancer therapy.

Authors:  Mircea Ivan; Melissa L Fishel; Oana M Tudoran; Karen E Pollok; Xue Wu; Paul J Smith
Journal:  Semin Cancer Biol       Date:  2021-10-07       Impact factor: 15.707

Review 2.  Hypoxia-inducible factors: master regulators of hypoxic tumor immune escape.

Authors:  Qinghua Wu; Li You; Eugenie Nepovimova; Zbynek Heger; Wenda Wu; Kamil Kuca; Vojtech Adam
Journal:  J Hematol Oncol       Date:  2022-06-03       Impact factor: 23.168

3.  Identification of Hypoxia-Related Subtypes, Establishment of Prognostic Models, and Characteristics of Tumor Microenvironment Infiltration in Colon Cancer.

Authors:  Changjing Wang; Yujie Tang; Hongqing Ma; Sisi Wei; Xuhua Hu; Lianmei Zhao; Guiying Wang
Journal:  Front Genet       Date:  2022-06-17       Impact factor: 4.772

Review 4.  Hypoxia-inducible factors: cancer progression and clinical translation.

Authors:  Elizabeth E Wicks; Gregg L Semenza
Journal:  J Clin Invest       Date:  2022-06-01       Impact factor: 19.456

5.  Hypoxia Induces Autophagy in Human Dendritic Cells: Involvement of Class III PI3K/Vps34.

Authors:  Sara Monaci; Federica Coppola; Daniela Rossi; Gaia Giuntini; Irene Filippi; Giuseppe Marotta; Silvano Sozzani; Fabio Carraro; Antonella Naldini
Journal:  Cells       Date:  2022-05-19       Impact factor: 7.666

Review 6.  The Synergistic Cooperation between TGF-β and Hypoxia in Cancer and Fibrosis.

Authors:  Pramod Mallikarjuna; Yang Zhou; Maréne Landström
Journal:  Biomolecules       Date:  2022-04-25

Review 7.  The Effect of Hypoxia and Hypoxia-Associated Pathways in the Regulation of Antitumor Response: Friends or Foes?

Authors:  Raefa Abou Khouzam; Rania Faouzi Zaarour; Klaudia Brodaczewska; Bilal Azakir; Goutham Hassan Venkatesh; Jerome Thiery; Stéphane Terry; Salem Chouaib
Journal:  Front Immunol       Date:  2022-02-08       Impact factor: 7.561

8.  Comprehensive analysis of the correlations of S100B with hypoxia response and immune infiltration in hepatocellular carcinoma.

Authors:  Jia Yan; Ya Jun Huang; Qing Yu Huang; Peng Xia Liu; Chang Shan Wang
Journal:  PeerJ       Date:  2022-03-29       Impact factor: 2.984

9.  HIF inhibitor 32-134D eradicates murine hepatocellular carcinoma in combination with anti-PD1 therapy.

Authors:  Shaima Salman; David J Meyers; Elizabeth E Wicks; Sophia N Lee; Emmanuel Datan; Aline M Thomas; Nicole M Anders; Yousang Hwang; Yajing Lyu; Yongkang Yang; Walter Jackson; Dominic Dordai; Michelle A Rudek; Gregg L Semenza
Journal:  J Clin Invest       Date:  2022-05-02       Impact factor: 19.456

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.